metastatic/advanced RCC (mRCC) - 1st line (L1) | |
mRCC - L1 - PDL1 positive | |
atezolizumab based treatment | |
atezolizumab alone | IMmotion-150 ... |
atezolizumab plus bevacizumab | IMmotion-151 ... IMmotion-150 ... |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -